EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study

Nhi Thi Hong Nguyen iD, Phung-Anh Nguyen iD, Chih-Wei Huang iD, Ching-Huan Wang, Ming-Chin Lin iD, Min-Huei Hsu, Hoang Bui Bao, Shuo-Chen Chien, Hsuan-Chia Yang iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043814 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Nhi Thi Hong Nguyen und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Care Administration, College of Management, Taipei Medical University, Taipei 11031, Taiwan. Hauptthemen laut MEDLINE: Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Endometrial Neoplasms, Hypertension. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Ministry of Education in Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The chronic receipt of renin-angiotensin-aldosterone system (RAAS) inhibitors including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been assumed to be associated with a significant decrease in overall gynecologic cancer risks. This study aimed to investigate the associations of long-term RAAS inhibitors use with gynecologic cancer risks. A large population-based case-control study was conducted from claim databases of Taiwan’s Health and Welfare Data Science Center (2000–2016) and linked with Taiwan Cancer Registry (1979–2016). Each eligible case was matched with four controls using propensity matching score method for age, sex, month, and year of diagnosis. We applied conditional logistic regression with 95% confidence intervals to identify the associations of RAAS inhibitors use with gynecologic cancer risks. The statistical significance threshold was p < 0.05. A total of 97,736 gynecologic cancer cases were identified and matched with 390,944 controls. The adjusted odds ratio for RAAS inhibitors use and overall gynecologic cancer was 0.87 (95% CI: 0.85–0.89). Cervical cancer risk was found to be significantly decreased in the groups aged 20–39 years (aOR: 0.70, 95% CI: 0.58–0.85), 40–64 years (aOR: 0.77, 95% CI: 0.74–0.81), ≥65 years (aOR: 0.87, 95% CI: 0.83–0.91), and overall (aOR: 0.81, 95% CI: 0.79–0.84). Ovarian cancer risk was significantly lower in the groups aged 40–64 years (aOR: 0.76, 95% CI: 0.69–0.82), ≥65 years (aOR: 0.83, 95% CI: 0.75–092), and overall (aOR: 0.79, 95% CI: 0.74–0.84). However, a significantly increased endometrial cancer risk was observed in users aged 20–39 years (aOR: 2.54, 95% CI: 1.79–3.61), 40–64 years (aOR: 1.08, 95% CI: 1.02–1.14), and overall (aOR: 1.06, 95% CI: 1.01–1.11). There were significantly reduced risks of gynecologic cancers with ACEIs users in the groups aged 40–64 years (aOR: 0.88, 95% CI: 0.84–0.91), ≥65 years (aOR: 0.87, 95% CI: 0.83–0.90), and overall (aOR: 0.88, 95% CI: 0.85–0.80), and ARBs users aged 40-64 years (aOR: 0.91, 95% CI: 0.86–0.95). Our case-control study demonstrated that RAAS inhibitors use was associated with a significant decrease in overall gynecologic cancer risks. RAAS inhibitors exposure had lower associations with cervical and ovarian cancer risks, and increased endometrial cancer risk. ACEIs/ARBs use was found to have a preventive effect against gynecologic cancers. Future clinical research is needed to establish causality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsEndometrial NeoplasmsHypertensionOvarian NeoplasmsRenin-Angiotensin SystemFemaleHumansCase-Control StudiesRisk Factors

Stichwörter der Autor:innen

ACEIsARBscervical cancerendometrial cancergynecologic cancer riskovarian cancerrenin-angiotensin-aldosterone system

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • School of Health Care Administration, College of Management, Taipei Medical University, Taipei 11031, Taiwan.
  • Health Personnel Training Institute, University of Medicine and Pharmacy, Hue University, Hue 491-20, Vietnam.
  • Clinical Data Center, Office of Data Science, Taipei Medical University, Taipei 106339, Taiwan.
  • Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei 11031, Taiwan.
  • International Center for Health Information Technology (ICHIT), College of Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.
  • Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 106339, Taiwan.

ORCID-Profile: Nhi Thi Hong Nguyen, Phung-Anh Nguyen, Chih-Wei Huang, Ming-Chin Lin, Hsuan-Chia Yang

Förderung

  • National Science and Technology Council
  • Ministry of Education in Taiwan

Zitieren

APA

Nguyen, N. T. H., Nguyen, P. A., Huang, C. W., Wang, C. H., Lin, M. C., Hsu, M. H., Bao, H. B., Chien, S. C., & Yang, H. C. (2023). Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043814

Vancouver

Nguyen NTH, Nguyen PA, Huang CW, Wang CH, Lin MC, Hsu MH, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043814

BibTeX
@article{Nguyen2023,
  author = {Nguyen, Nhi Thi Hong and Nguyen, Phung-Anh and Huang, Chih-Wei and Wang, Ching-Huan and Lin, Ming-Chin and Hsu, Min-Huei and Bao, Hoang Bui and Chien, Shuo-Chen and Yang, Hsuan-Chia},
  title = {Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043814}
}
Kostenlos starten →